IMV Inc. (IMVIQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.2800 - Volume
211 - Avg. Volume
1,015 - Market Cap (intraday)
11 - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-4.5500 - Earnings Date Mar 14, 2024 - Mar 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
www.imv-inc.comRecent News: IMVIQ
Performance Overview: IMVIQ
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMVIQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMVIQ
Valuation Measures
Market Cap
117.00
Enterprise Value
7.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.78%
Return on Equity (ttm)
-508.58%
Revenue (ttm)
329k
Net Income Avi to Common (ttm)
-37.99M
Diluted EPS (ttm)
-4.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
21.22M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-21.51M
Research Analysis: IMVIQ
Company Insights: IMVIQ
IMVIQ does not have Company Insights